CT-guided 125I brachytherapy for hepatocellular carcinoma in high-risk locations after transarterial chemoembolization combined with microwave ablation: a propensity score-matched study
CT-guided 125I brachytherapy for HCC in high-risk locations after TACE combined with MWA: a propensity score-matched study
Abstract
Objectives: This study aimed to evaluate the safety and efficacy of 125I brachytherapy combined with transarterial chemoembolization (TACE) and microwave ablation (MWA) for unresectable hepatocellular carcinoma (HCC) in high-risk locations.
Methods: After 1:2 propensity score matching (PSM), this retrospectively study analyzed 49 patients who underwent TACE +MWA+125I brachytherapy (group A) and 98 patients who only received TACE +MWA (group B). The evaluated outcomes were progression-free survival (PFS), overall survival (OS), and treatment complications. Cox proportional hazards regression analysis survival was used to compare the two groups.
Results: The patients in group A showed a longer PFS than group B (7.9 vs 3.3 months, P=0.007). No significant differences were observed in median OS between the two groups (P=0.928). The objective response rate (ORR), disease control rate of tumors in high-risk locations, and the ORR of intrahepatic tumors were 67.3%, 93.9%, and 51.0%, respectively, in group A, and 38.8%, 79.6% and 29.6%, respectively, in group B (P<0.001, P=0.025 and P=0.011, respectively). TACE-MWA-125I (HR=0.479, P<0.001) was a significant favorable prognostic factor that affected PFS. The present of portal vein tumor thrombosis was an independent prognostic factor for PFS (HR=1.625, P=0.040). The BCLC stage (BCLC C vs B) was an independent factor affecting OS (HR=1.941, P=0.038). The incidence of complications was similar between the two groups, except that the incidence of abdominal pain was reduced in the group A (P=0.007).
Conclusions: TACE-MWA-125I resulted in longer PFS and better tumor control than did TACE-MWA in patients with unresectable hepatocellular carcinoma in high-risk locations.
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Zixiong Chen, Xiaobo Fu, zhen-Kang Qiu, Maoyuan Mu, Weiwei Jiang, Guisong Wang, Zhihui zhong, Han Qi, Fei Gao

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
License to Publish
Please read the terms of this agreement, print, initial page 1, sign page 3, scan and send the document as one file attached to an e-mail to gsersa@onko-i.si